Mechanisms of acquired resistance to tyrosine kinase inhibitors

Hegedus, 2002, Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1, Biochim Biophys Acta, 1587, 318, 10.1016/S0925-4439(02)00095-9

Yoshida, 2010, Targeting epidermal growth factor receptor: central signaling kinase in lung cancer, Biochem Pharmacol, 80, 613, 10.1016/j.bcp.2010.05.014

Grimminger, 2010, Targeting non-malignant disorders with tyrosine kinase inhibitors, Nat Rev Drug Discov, 9, 956, 10.1038/nrd3297

Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762

Hunter, 1998, The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease, Philos Trans R Soc Lond B Biol Sci, 353, 583, 10.1098/rstb.1998.0228

Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011

Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8

Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat Rev Cancer, 4, 361, 10.1038/nrc1360

Krause, 2005, Tyrosine kinases as targets for cancer therapy, N Engl J Med, 353, 172, 10.1056/NEJMra044389

Reiter, 2007, Tyrosine kinases as therapeutic targets in BCR–ABL negative chronic myeloproliferative disorders, Curr Drug Targets, 8, 205, 10.2174/138945007779940124

Wong, 2005, Inhibitors of the tyrosine kinase signaling cascade for asthma, Curr Opin Pharmacol, 5, 264, 10.1016/j.coph.2005.01.009

Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010; doi:10.1186/1476-4598-9-75.

Wang, 2010, Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins, Curr Drug Metab, 11, 618, 10.2174/138920010792927316

Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc Chem Res, 41, 98, 10.1021/ar700108g

Arora, 2005, Role of tyrosine kinase inhibitors in cancer therapy, J Pharmacol Exp Ther, 315, 971, 10.1124/jpet.105.084145

Shawver, 2002, Smart drugs: tyrosine kinase inhibitors in cancer therapy, Cancer Cell, 1, 117, 10.1016/S1535-6108(02)00039-9

Ocana, 2011, Preclinical development of molecular-targeted agents for cancer, Nat Rev Clin Oncol, 8, 200, 10.1038/nrclinonc.2010.194

Hanfstein, 2011, Dynamics of mutant BCR–ABL-positive clones after cessation of tyrosine kinase inhibitor therapy, Haematologica, 96, 360, 10.3324/haematol.2010.030999

Tanaka, 2008, Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation, Expert Rev Anticancer Ther, 8, 1387, 10.1586/14737140.8.9.1387

Suda, 2009, EGFR T790M mutation: a double role in lung cancer cell survival?, J Thorac Oncol, 4, 1, 10.1097/JTO.0b013e3181913c9f

Yun, 2007, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, Cancer Cell, 11, 217, 10.1016/j.ccr.2006.12.017

Godin-Heymann, 2007, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation, Cancer Res, 67, 7319, 10.1158/0008-5472.CAN-06-4625

Rho, 2010, Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation, Mol Cancer Ther, 9, 3233, 10.1158/1535-7163.MCT-10-0625

Uramoto, 2011, Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma, Lung Cancer, 73, 361, 10.1016/j.lungcan.2011.01.008

Oxnard, 2011, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, 17, 1616, 10.1158/1078-0432.CCR-10-2692

Yamada, 2010, Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer, Clin Cancer Res, 16, 174, 10.1158/1078-0432.CCR-09-1204

Manrique, 2011, Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors, Clin Exp Med, 11, 55, 10.1007/s10238-010-0101-x

Kim, 2009, Structural modeling of V299L and E459K Bcr–Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations, Leuk Res, 33, 1260, 10.1016/j.leukres.2008.12.017

Regales, 2007, Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors, PLoS One, 2, e810, 10.1371/journal.pone.0000810

Alexandra, 2008, Mechanisms of resistance to EGFR tyrosine kinase inhibitors:implications for patient selection and drug combination strategies, Targeted Oncology, 3, 9

Settleman, 2007, Drugging the bad “AKT-TOR" to overcome TKI-resistant lung cancer, Cancer Cell, 12, 6, 10.1016/j.ccr.2007.06.010

Mulloy, 2007, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib, Cancer Res, 67, 2325, 10.1158/0008-5472.CAN-06-4293

Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer, 7, 169, 10.1038/nrc2088

Burke, 2011, Current status of agents active against the T315I chronic myeloid leukemia phenotype, Expert Opin Emerg Drugs, 16, 85, 10.1517/14728214.2011.531698

Hughes, 2009, Monitoring disease response to tyrosine kinase inhibitor therapy in CML, Hematology Am Soc Hematol Educ Program, 477, 10.1182/asheducation-2009.1.477

La Rosee, 2010, Resistance to imatinib: mutations and beyond, Semin Hematol, 47, 335, 10.1053/j.seminhematol.2010.06.005

Apperley, 2007, Mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, 8, 1018, 10.1016/S1470-2045(07)70342-X

Mancini, 2011, A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib, J Pharmacol Exp Ther, 336, 596, 10.1124/jpet.110.172536

Agrawal, 2010, Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the “best" therapy?, Curr Oncol Rep, 12, 302, 10.1007/s11912-010-0116-1

Liegl, 2008, Heterogeneity of kinase inhibitor resistance mechanisms in GIST, J Pathol, 216, 64, 10.1002/path.2382

Cassier, 2010, Molecular response prediction in gastrointestinal stromal tumors, Target Oncol, 5, 29, 10.1007/s11523-010-0134-9

Corless, 2004, Biology of gastrointestinal stromal tumors, J Clin Oncol, 22, 3813, 10.1200/JCO.2004.05.140

Corless, 2005, PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib, J Clin Oncol, 23, 5357, 10.1200/JCO.2005.14.068

Mol, 2004, Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors, Curr Opin Drug Discov Devel, 7, 639

Gajiwala, 2009, KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients, Proc Natl Acad Sci USA, 106, 1542, 10.1073/pnas.0812413106

Sun, 2009, The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction, J Biol Chem, 284, 11039, 10.1074/jbc.M808058200

Antonescu, 2007, L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition, Int J Cancer, 121, 257, 10.1002/ijc.22681

Prenen, 2006, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate, Clin Cancer Res, 12, 2622, 10.1158/1078-0432.CCR-05-2275

Sjolund, 2010, Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability, World J Surg, 34, 2090, 10.1007/s00268-010-0639-5

Pratz, 2010, FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML, Blood, 115, 1425, 10.1182/blood-2009-09-242859

Stirewalt, 2010, Receptor tyrosine kinase alterations in AML – biology and therapy, Cancer Treat Res, 145, 85, 10.1007/978-0-387-69259-3_6

Youssoufian, 2010, Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10, Cancer, 116, 1013, 10.1002/cncr.24787

Piloto, 2007, Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways, Blood, 109, 1643, 10.1182/blood-2006-05-023804

Heidel, 2006, Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain, Blood, 107, 293, 10.1182/blood-2005-06-2469

Weisberg, 2010, Drug resistance in mutant FLT3-positive AML, Oncogene, 29, 5120, 10.1038/onc.2010.273

von Bubnoff, 2009, FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro, Cancer Res, 69, 3032, 10.1158/0008-5472.CAN-08-2923

Frohling, 2007, Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles, Cancer Cell, 12, 501, 10.1016/j.ccr.2007.11.005

Bagrintseva, 2004, Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells, Blood, 103, 2266, 10.1182/blood-2003-05-1653

Cools, 2004, Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia, Cancer Res, 64, 6385, 10.1158/0008-5472.CAN-04-2148

Quentmeier H, Eberth S, Romani J, Zaborski M. Drexler HG. BCR–ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011; doi:10.1186/1756-8722-4-6.

Horn, 2008, Stocking C, et al. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells, Oncogene, 27, 4096, 10.1038/onc.2008.40

Tiseo, 2011, EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations, Lung Cancer, 71, 241, 10.1016/j.lungcan.2010.11.014

Costa, 2007, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations, PLoS Med, 4, 1669, 10.1371/journal.pmed.0040315

Nowak, 2010, SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations, Blood, 115, 1049, 10.1182/blood-2009-03-210377

Kosaka, 2011, Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer, J Biomed Biotechnol, 10.1155/2011/165214

Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009; doi:10.1186/1748-717X-4-69.

Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci USA, 104, 20932, 10.1073/pnas.0710370104

Qi, 2011, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors, Cancer Res, 71, 1081, 10.1158/0008-5472.CAN-10-1623

Turke, 2010, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, 17, 77, 10.1016/j.ccr.2009.11.022

Corso, 2010, Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition, Mol Cancer, 10.1186/1476-4598-9-121

Cepero, 2010, MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors, Cancer Res, 70, 7580, 10.1158/0008-5472.CAN-10-0436

McDermott, 2010, Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency, Cancer Res, 70, 1625, 10.1158/0008-5472.CAN-09-3620

Suda, 2010, Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer, Clin Cancer Res, 16, 5489, 10.1158/1078-0432.CCR-10-1371

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; doi:10.1126/scitranslmed.3002003.

Liska, 2011, HGF rescues colorectal cancer cells from EGFR inhibition via MET activation, Clin Cancer Res, 17, 472, 10.1158/1078-0432.CCR-10-0568

Nam, 2010, The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability, Carcinogenesis, 31, 1531, 10.1093/carcin/bgq133

Volpe, 2009, Imatinib resistance in CML, Cancer Lett, 274, 1, 10.1016/j.canlet.2008.06.003

Sharma, 2010, Mutations in ABL kinase domain are associated with inferior progression-free survival, Leuk Lymphoma, 51, 1072, 10.3109/10428191003729741

Breccia, 2009, Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem, Cardiovasc Hematol Disord Drug Targets, 9, 21, 10.2174/187152909787581363

Mason, 2010, Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR–Abl, Cancer Res, 70, 8066, 10.1158/0008-5472.CAN-10-0608

Virgili, 2011, Imatinib sensitivity in BCR–ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele, Cancer Res, 71, 5381, 10.1158/0008-5472.CAN-11-0068

Chung, 2011, Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs, Lung Cancer, 73, 176, 10.1016/j.lungcan.2010.11.011

Kwak, 2006, Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas, Clin Cancer Res, 12, 4283, 10.1158/1078-0432.CCR-06-0189

Donev, 2011, Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer, Clin Cancer Res, 17, 2260, 10.1158/1078-0432.CCR-10-1993

Mink, 2010, Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs, Mol Cancer Res, 8, 809, 10.1158/1541-7786.MCR-09-0460

Yang, 2011, Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells, J Gastrointest Surg, 15, 942, 10.1007/s11605-011-1504-z

Dumka, 2009, Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib, Leuk Lymphoma, 50, 2017, 10.3109/10428190903147637

Nagaraj, 2010, Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis, Mol Cancer Ther, 9, 2322, 10.1158/1535-7163.MCT-09-1212

Suzuki, 2010, BCR–ABL-independent and RAS/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4, Eur J Haematol, 84, 229, 10.1111/j.1600-0609.2009.01387.x

Carella, 2010, Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?, Ann Hematol, 89, 531, 10.1007/s00277-010-0907-3

Kim, 2010, Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells, Cancer Lett, 296, 150, 10.1016/j.canlet.2010.04.006

Nishioka, 2010, Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene, Leukemia, 24, 1631, 10.1038/leu.2010.145

Vivanco, 2010, The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation, Proc Natl Acad Sci USA, 107, 6459, 10.1073/pnas.0911188107

Mukohara, 2011, Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer, Cancer Sci, 102, 1, 10.1111/j.1349-7006.2010.01711.x

Xia, 2006, A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer, Proc Natl Acad Sci USA, 103, 7795, 10.1073/pnas.0602468103

Morgillo, 2011, Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors, Lung Cancer, 71, 283, 10.1016/j.lungcan.2010.06.005

Yang, 2009, Analysis of differentially expressed proteins in self-paired sera of advanced non-small cell lung cancer patients responsive to Gefinitib, Zhongguo Fei Ai Za Zhi, 12, 765

Chen, 2011, Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells, J Pharmacol Exp Ther, 337, 155, 10.1124/jpet.110.175786

Ichihara, 2009, Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo, Cancer Res, 69, 5091, 10.1158/0008-5472.CAN-08-4204

Jabbour, 2011, Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors, Cancer, 117, 897, 10.1002/cncr.25656

Leslie, 2005, Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol Appl Pharmacol, 204, 216, 10.1016/j.taap.2004.10.012

Vasconcelos, 2011, Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients, Cytometry B Clin Cytom, 80, 158, 10.1002/cyto.b.20580

Azzariti, 2010, Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences, Cancer Chemother Pharmacol, 65, 335, 10.1007/s00280-009-1039-0

Davies, 2009, Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters, Leukemia, 23, 1999, 10.1038/leu.2009.166

Graber-Maier A, Gutmann H, Drewe J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as Imatinib. Mol Pharm 2010; doi:10.1021/mp100040f.

Carcaboso, 2010, Calabrese C, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas, Cancer Res, 70, 4499, 10.1158/0008-5472.CAN-09-4264

Hegedus, 2009, Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties, Br J Pharmacol, 158, 1153, 10.1111/j.1476-5381.2009.00383.x

Yang, 2010, P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor, Drug Metab Lett, 4, 201, 10.2174/187231210792928279

Brozik, 2011, Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?, Expert Opin Drug Metab Toxicol, 7, 623, 10.1517/17425255.2011.562892

Melo, 2007, Resistance to imatinib mesylate in chronic myeloid leukaemia, Cancer Lett, 249, 121, 10.1016/j.canlet.2006.07.010

White, 2007, Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity, Blood, 110, 4064, 10.1182/blood-2007-06-093617

White, 2006, OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib, Blood, 108, 697, 10.1182/blood-2005-11-4687

Thomas, 2004, Active transport of imatinib into and out of cells: implications for drug resistance, Blood, 104, 3739, 10.1182/blood-2003-12-4276

Kuang, 2010, Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance, Biochem Pharmacol, 79, 154, 10.1016/j.bcp.2009.08.021

Dai, 2008, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2, Cancer Res, 68, 7905, 10.1158/0008-5472.CAN-08-0499

Tiwari, 2009, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters, Biochem Pharmacol, 78, 153, 10.1016/j.bcp.2009.04.002

Noguchi, 2009, Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib, Cancer Sci, 100, 1701, 10.1111/j.1349-7006.2009.01213.x